Midjourney's Bold Leap: From AI Art to Full-Body Ultrasound Scanner
Generative AI giant Midjourney unveils a futuristic 'dunk-tank' ultrasound system, the Midjourney Scanner, aiming to map the entire human body in 60 seconds.
✨ This content was summarized and interpreted by AI; it may contain errors — please verify accuracy with the original sources. Learn more
Listen to this story
Midjourney, the generative AI powerhouse known for creating stunning images, has made an audacious leap into medical hardware, unveiling its "Midjourney Scanner" – a futuristic, dunk-tank ultrasound system designed to map the entire human body in just 60 seconds. Announced in mid-June 2026 under the new Midjourney Medical division, the company touts its "Ultrasonic CT" as a revolutionary full-body imaging method, claiming it is "in many ways superior to even MRI machines" without using radiation or magnetic fields, and at a fraction of the cost.
This dramatic pivot from AI art to advanced diagnostics, however, leaves a multitude of critical questions unanswered. While the concept video depicts a seamless, minute-long scan, the current Gen-1 prototype reportedly takes approximately 20 minutes and has only been tested on about a dozen individuals. Crucially, the device currently lacks regulatory clearance for diagnostic use, a significant hurdle in the highly regulated medical field. To circumvent immediate stringent medical device regulations, Midjourney plans to initially offer "body composition maps" at branded "Midjourney Spas," with the first location slated for San Francisco by late 2027.
The underlying imaging technology itself is not Midjourney's proprietary generative AI, but rather licensed "ultrasound-on-chip" technology from Butterfly Network under a multi-million dollar co-development deal signed in November 2025. While the company envisions a global fleet of 50,000 scanners by 2031, capable of a billion scans monthly and potentially cutting healthcare costs by half, medical experts remain cautious. Radiologists highlight that current image quality appears insufficient for detecting small tumors, and widespread asymptomatic screening could lead to a deluge of incidental findings, creating more anxiety and follow-up costs than benefits. Midjourney's foray represents a bold vision for accessible preventative health, but the chasm between ambitious claims and rigorously validated medical utility remains vast, demanding far more than sleek videos to bridge.